EXCLUSIVE: Adial Pharma Announces Key Patent To Combine Genetic Diagnostic With Lead Drug For Alcohol Addiction
Portfolio Pulse from Vandana Singh
Adial Pharmaceuticals Inc (NASDAQ:ADIL) has been awarded a patent for combining its proprietary genetic diagnostic with its lead investigational product AD04, for the treatment of alcohol and opioid use disorders. The patent is seen as a significant milestone in the company's pursuit to provide more effective treatments. The company's shares are up 3.06% at $2.86.
October 19, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adial Pharmaceuticals has been awarded a key patent for its lead drug, potentially boosting its market position. The company's shares are up 3.06%.
The award of a key patent for Adial Pharmaceuticals' lead drug AD04 is a significant development for the company. This could potentially boost its market position and competitiveness in the treatment of alcohol and opioid use disorders. The news has already had a positive impact on the company's stock price, which is up 3.06%.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100